AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain ...

AbbVie ABBV has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic ...

Wondering if AbbVie is still a smart buy after its huge run, or if the value has already been squeezed out of the stock? Let ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $120.0 and $250.0 for AbbVie, spanning the last three months.

BofA lowered the firm’s price target on AbbVie (ABBV) to $233 from $248 and keeps a Neutral rating on the shares. The firm, ...

AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and ...

Close to two years after AbbVie handed over $48 million for the rights to OSE Immunotherapeutics’ inflammation drug, the Big ...

Lastly, AbbVie is a fantastic income stock. The company is part of the group of Dividend Kings, corporations that have ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

The Intravenous Immunoglobulin (IVIG) market across the 7MM was valued at around USD 7,384 million in 2025 and is expected to ...

Discover why AbbVie (ABBV) is rated Strong Buy, with robust 2025 growth, diversified revenues, and attractive valuation.